Chugai Files Additional Indication Of Herceptin For Breast Cancer Adjuvant Chemotherapy
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceuticals filed a public knowledge-based application for the approval of an additional indication of a once-a-week administration for postoperative adjuvant chemotherapy in breast cancer that overexpresses HER2 for Herceptin (trastuzumab) Feb. 7